AAAAAA

   
Results: 1-14 |
Results: 14
Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study
Authors: Meredith, RF Alvarez, RD Partridge, EE Khazaeli, MB Lin, CY Macey, DJ Austin, JM Kilgore, LC Grizzle, WE Schlom, J LoBuglio, AF
Citation: Rf. Meredith et al., Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study, CANC BIO R, 16(4), 2001, pp. 305-315
A pilot trial of vitaxin, a humanized anti-vitronectin receptor (anti alpha(v)beta(3)) antibody in patients with metastatic cancer
Authors: Posey, JA Khazaeli, MB DelGrosso, A Saleh, MN Lin, CY Huse, W LoBuglio, AF
Citation: Ja. Posey et al., A pilot trial of vitaxin, a humanized anti-vitronectin receptor (anti alpha(v)beta(3)) antibody in patients with metastatic cancer, CANC BIO R, 16(2), 2001, pp. 125-132
Expression of human endogenous retrovirus K envelope transcripts in human breast cancer
Authors: Wang-Johanning, F Frost, AR Johanning, GL Khazaeli, MB LoBuglio, AF Shaw, DR Strong, TV
Citation: F. Wang-johanning et al., Expression of human endogenous retrovirus K envelope transcripts in human breast cancer, CLIN CANC R, 7(6), 2001, pp. 1553-1560
Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy
Authors: Czuczman, MS Grillo-Lopez, AJ McLaughlin, P White, CA Saleh, M Gordon, L LoBuglio, AF Rosenberg, J Alkuzweny, B Maloney, D
Citation: Ms. Czuczman et al., Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy, ANN ONCOL, 12(1), 2001, pp. 109-114
Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
Authors: Robert, F Ezekiel, MP Spencer, SA Meredith, RF Bonner, JA Khazaeli, MB Saleh, MN Carey, D LoBuglio, AF Wheeler, RH Cooper, MR Waksal, HW
Citation: F. Robert et al., Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer, J CL ONCOL, 19(13), 2001, pp. 3234-3243
Induction of anti-tumor immunity by intrasplenic administration of a carcinoembryonic antigen DNA vaccine
Authors: White, SA LoBuglio, AF Arani, RB Pike, MJ Moore, SE Barlow, DL Conry, RM
Citation: Sa. White et al., Induction of anti-tumor immunity by intrasplenic administration of a carcinoembryonic antigen DNA vaccine, J GENE MED, 2(2), 2000, pp. 135-140
Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine
Authors: Conry, RM Allen, KO Lee, SW Moore, SE Shaw, DR LoBuglio, AF
Citation: Rm. Conry et al., Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine, CLIN CANC R, 6(1), 2000, pp. 34-41
SEREX analysis for tumor antigen identification in a mouse model of adenocarcinoma
Authors: Hampton, TA Conry, RM Khazaeli, MB Shaw, DR Curiel, DT LoBuglio, AF Strong, TV
Citation: Ta. Hampton et al., SEREX analysis for tumor antigen identification in a mouse model of adenocarcinoma, CANC GENE T, 7(3), 2000, pp. 446-455
Enhanced apoptosis with combination C225/radiation treatment serves as theimpetus for clinical investigation in head and neck cancers
Authors: Bonner, JA Raisch, KP Trummell, HQ Robert, F Meredith, RF Spencer, SA Buchsbaum, DJ Saleh, MN Stackhouse, MA LoBuglio, AF Peters, GE Carroll, WR Waksal, HW
Citation: Ja. Bonner et al., Enhanced apoptosis with combination C225/radiation treatment serves as theimpetus for clinical investigation in head and neck cancers, J CL ONCOL, 18(21), 2000, pp. 47S-53S
Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-Doxorubicin inpatients with Lewis Y-expressing epithelial tumors
Authors: Saleh, MN Sugarman, S Murray, J Ostroff, JB Healey, D Jones, D Daniel, CR LeBherz, D Brewer, H Onetto, N LoBuglio, AF
Citation: Mn. Saleh et al., Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-Doxorubicin inpatients with Lewis Y-expressing epithelial tumors, J CL ONCOL, 18(11), 2000, pp. 2282-2292
A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia
Authors: Saleh, MN Gutheil, J Moore, M Bunch, PW Butler, J Kunkel, L Grillo-Lopez, AJ LoBuglio, AF
Citation: Mn. Saleh et al., A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia, SEMIN ONCOL, 27(6), 2000, pp. 99-103
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration
Authors: Conry, RM Khazaeli, MB Saleh, MN Allen, KO Barlow, DL Moore, SE Craig, D Arani, RB Schlom, J LoBuglio, AF
Citation: Rm. Conry et al., Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration, CLIN CANC R, 5(9), 1999, pp. 2330-2337
Phase II study of interferon-enhanced I-131-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer
Authors: Meredith, RF Khazaeli, MB Macey, DJ Grizzle, WE Mayo, M Schlom, J Russell, CD LoBuglio, AF
Citation: Rf. Meredith et al., Phase II study of interferon-enhanced I-131-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer, CLIN CANC R, 5(10), 1999, pp. 3254S-3258S
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
Authors: Czuczman, MS Grillo-Lopez, AJ White, CA Saleh, M Gordon, L LoBuglio, AF Jonas, C Klippenstein, D Dallaire, B Varns, C
Citation: Ms. Czuczman et al., Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy, J CL ONCOL, 17(1), 1999, pp. 268-276
Risultati: 1-14 |